A new guidance document from US FDA provides new recommendations on device labeling and safety testing for heparin-containing products that are intended to reduce the risk of accidental overdoses. The Sept. 20 document aligns FDA guidance with safety-driven revisions to US Pharmacopeia (USP) monographs on heparin sodium, heparin lock flush solution and heparin sodium injections.
Regulators became concerned about the issue after investigations into product-related heparin overdose errors revealed that a major contributing factor had been the way product labels incorporated drug strength information. Additionally,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?